1. Pictilisib Enhances the Antitumor Effect of Doxorubicin and Prevents Tumor-Mediated Bone Destruction by Blockade of PI3K/AKT Pathway
   Chao Liang et al, 2021, Front. Oncol. CrossRef
2. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study.
   Peiliang Wang et al, 2021, Front Oncol CrossRef
3. Case Report: Anlotinib Therapy in a Patient With Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAFV600E Mutations
   Yanjun Su et al, 2021, Front. Oncol. CrossRef
4. Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma
   Zhexun Huang et al, 2021, Journal of Genetics and Genomics CrossRef
5. Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways
   Zhongling Zhu et al, 2021, Front. Pharmacol. CrossRef
6. Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials
   Lisha Mou et al, 2021, Front. Oncol. CrossRef
7. Anlotinib-Induced Hypertension: Current Concepts and Future Prospects
   Bing Lv et al, 2021, CPD CrossRef
8. Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
   Mengqiu Tang et al, 2021, Lipids Health Dis CrossRef
9. Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report
   Shengnan Zheng et al, 2022 CrossRef
10. Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions
    Mohd Imran et al, 2021, Biomedicines CrossRef
11. First-Line Anlotinib Combined with Stereotactic Body Radiation Therapy for an Octogenarian with Pulmonary Carcinosarcoma
    Long Liang et al, 2022, CMAR CrossRef
12. NUT midline carcinoma as a primary lung tumor treated with anlotinib combined with palliative radiotherapy: a case report.
    Jin Jiang et al, 2022, Diagn Pathol CrossRef
13. FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?
    Csongor G. Lengyel et al, 2022, Life CrossRef
14. Anlotinib inhibits the proliferation, migration and invasion, and induces apoptosis of breast cancer cells by downregulating TFAP2C
    Fuxiao Fang et al, 2021, Oncol Lett CrossRef
15. The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Advanced Lung Cancer: A Retrospective Cohort Study
    Lei Li et al, 2022, Computational and Mathematical Methods in Medicine CrossRef
16. Sequential occurrence of T790M mutation and small cell lung cancer transformation in EGFR-positive lung adenocarcinoma: A case report
    Er Hong et al, 2022, WJCC CrossRef
17. Application of physiologically based pharmacokinetic modelling for the prediction of drug–drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes
    Zhiping Jin et al, 2022, Basic Clin Pharma Tox CrossRef
18. Sequential occurrence of T790M mutation and small cell lung cancer transformation in EGFR-positive lung adenocarcinoma: A case report
    Er Hong et al, 2022, WJCC CrossRef
19. The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors
    Suying Lu et al, 2022, Front. Pharmacol. CrossRef
20. Changing Landscape of Systemic Therapy in Biliary Tract Cancer
    Edward Woods et al, 2022, Cancers CrossRef
21. Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development
    Na Qu et al, 2022, Front. Endocrinol. CrossRef
22. Anlotinib attenuates experimental autoimmune encephalomyelitis mice model of multiple sclerosis via modulating the differentiation of Th17 and Treg cells
    Haoran Zhu et al, 2022, Immunopharmacology and Immunotoxicology CrossRef
23. null
    Tarang Patel et al, 2022 CrossRef
24. Long-Term Efficacy and Safety of Anlotinib as a Monotherapy and Combined Therapy for Advanced Sarcoma
    Weitao Yao et al, 2022, OTT CrossRef
25. Factors Influencing the Efficacy of Anlotinib in the Treatment of Advanced Non-Small Cell Lung Cancer
    Fengwu Chen et al, 2022, International J. of Pharmacology CrossRef
26. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
    Tiandong Kong et al, 2022, Invest New Drugs CrossRef
27. First line anlotinib plus liposomal doxorubicin for locally advanced or metastatic soft tissue sarcoma: A prospective, single-arm trial
    Xin Sun et al, 2022, Asian Pac J Trop Med CrossRef
28. Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib—a case report
    Yu-Feng Li et al, 2022, Front. Genet. CrossRef
29. MiR-210-3p targets CELF2 to facilitate progression of lung squamous carcinoma through PI3K/AKT pathway
    Qiang Zhang et al, 2022, Med Oncol CrossRef
30. Response to chemotherapy combined with anlotinib plus anlotinib maintenance in intra-abdominal desmoplastic small round cell tumors (IADSRCT): a case report and literature review
    Ke Cheng et al, 2022, BMC Gastroenterol CrossRef
31. A rapid and sensitive ultra‐performance liquid chromatography tandem mass spectrometry method for determination of anlotinib in plasma and dried blood spots: Method development, validation, and clinical application
    Ji Zhang et al, 2022, Rapid Comm Mass Spectrometry CrossRef
32. Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
    Fenge Jiang et al, 2022, Front. Pharmacol. CrossRef
33. Clinical Efficacy of Antianlotinib Combined with Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small-Cell Lung Cancer and Its Effect on Serum VEGF, CEA, and SCC-Ag
    Linghui He et al, 2022, Journal of Oncology CrossRef
34. Clinical Application of Anlotinib Combined with Docetaxel: Safe and Effective Treatment for Lung Carcinoma
    Xiang Ji et al, 2022, Disease Markers CrossRef
35. A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma
    Qingqing Li et al, 2022, CMAR CrossRef
36. SOD2 confers anlotinib resistance via regulation of mitochondrial damage in OSCC
    Shuai Li et al, 2022, Oral Diseases CrossRef
37. A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma
    Ning Li et al, 2022, BMC Med CrossRef
38. Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis.
    Tianyao Lei et al, 2023, Pharmacol Res CrossRef
39. Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement
    Ling Yu et al, 2023, Front. Pharmacol. CrossRef
40. Anlotinib in patients with relapsed or refractory thymic epithelial tumors: a study of 50 cases
    Chang-Lu Wang et al, 2022 CrossRef
41. Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China
    Jingyang Lin et al, 2023, PLoS ONE CrossRef
42. Case report: Primary alveolar soft-part sarcoma of the lung in a child
    Zhufei Xu et al, 2023, Front. Surg. CrossRef
43. Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance
    Mingzhao Wang et al, 2023, Thoracic Cancer CrossRef
44. MNK/eIF4E inhibition overcomes anlotinib resistance in non‐small cell lung cancer
    Qi Zhang et al, 2023, Fundamemntal Clinical Pharma CrossRef
45. Clinical Study of Antiangiogenic Agents in Advanced and Recurrent Cervical Cancer
    婷婷 胡, 2023, ACM CrossRef
46. Anlotinib succeeded in rescue therapy for hyperprogression induced by immune checkpoint inhibitors: a case report
    Lu Chen et al, 2023, Immunotherapy CrossRef
47. Oral Cavity Squamous Cell Carcinoma: An Update of the Pharmacological Treatment
    Martina Imbesi Bellantoni et al, 2023, Biomedicines CrossRef
48. Whole‐exome sequencing in primary pulmonary synovial sarcoma misdiagnosed as mesothelioma: A case report and literature review
    Di Wu et al, 2023, Thoracic Cancer CrossRef
49. Population Pharmacokinetics of Anlotinib, a Multiple Receptor Tyrosine Kinase Inhibitor, in Chinese Patients With Malignant Tumors
    Gaoqi Xu et al, 2023, The Journal of Clinical Pharma CrossRef
50. Efficacy and safety of anlotinib-based chemotherapy for locally advanced or metastatic anaplastic thyroid carcinoma
    Xucai Zheng et al, 2023, Endocrine CrossRef
51. A Pan-Cancer Analysis of Prognostic and Immunological Roles for Cell Death Genes
    Ye Hong et al, 2023, Genes CrossRef
52. The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Previously Treated Advanced Thymic Epithelia Tumors: A Retrospective Analysis
    Shuo Li et al, 2023, PRA CrossRef
53. Anlotinib Combined With Toripalimab as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Prospective, Multicenter, Phase II Study
    Cheng-Sheng Zhang et al, 2023 CrossRef
54. Penpulimab and anlotinib in an elderly patient with recurrent cervical cancer: a case report and literature review
    Gaoli Niu et al, 2023, Immunotherapy CrossRef
55. Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States
    Robert Jr. Roskoski, 2023, Pharmacological Research CrossRef
56. Drugs in the GIST Field (Therapeutic Targets and Clinical Trial Staging)
    Chen Huang et al, 2024, CDD CrossRef
57. Multi-targeted tyrosine kinase inhibitor reverses resistance to immunotherapy in hepatic sarcomatoid carcinoma
    Juan Chen et al, 2023, J Cancer Res Clin Oncol CrossRef
58. Changing landscape of anti-angiogenic therapy: Novel approaches and clinical perspectives
    Rajesh N. Gacche, 2023, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
59. Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib
    Shiting Li et al, 2023, DDDT CrossRef
60. Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study
    Mafei Kang et al, 2023 CrossRef
61. Recent advances progress of targeted drugs combined with radiotherapy for advanced non-small cell lung cancer: a review
    Jiamin Xu et al, 2023, Front. Oncol. CrossRef
62. Case report of radiotherapy combined with anlotinib and immunotherapy for a patient with esophageal cancer and esophageal fistula
    Lumei He et al, 2023, Applied Radiation and Isotopes CrossRef
63. Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis
    Lei Wang et al, 2024, Front. Pharmacol. CrossRef
64. null
    Vidya Sabale et al, 2024 CrossRef
65. METTL3 inhibitor STM2457 impairs tumor progression and enhances sensitivity to anlotinib in OSCC
    Lianlian Liu et al, 2024, Oral Diseases CrossRef
66. Angiogenesis signaling in endometriosis: Molecules, diagnosis and treatment (Review)
    Caixia Bo et al, 2024, Mol Med Rep CrossRef
67. Effective Treatment of Anlotinib Combined With Chemotherapy in Children With Desmoplastic Small Round Cell Tumor: A Case Series in a Single-center and Literature Review
    Xiao-Yu Jing et al, 2024 CrossRef
68. β‐Sitosterol attenuates anlotinib resistance in non‐small cell lung cancer cells by inhibiting miR‐181a‐3p/SHQ1 signaling
    Li‐huai Wang et al, 2024, Chem Biol Drug Des CrossRef
69. BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway
    Qingtao Meng et al, 2024, Journal of Bone Oncology CrossRef
70. A Pilot Study of Anlotinib as a Combination Treatment in Advanced Nasopharyngeal Carcinoma
    Rui Zhou et al, 2024, CCDT CrossRef
71. A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer
    Wei Zhang et al, 2023, Lung Cancer CrossRef
72. Radiotherapy plus temozolomide with or without anlotinib in H3K27M‐mutant diffuse midline glioma: A retrospective cohort study
    Chao Liu et al, 2024, CNS Neurosci Ther CrossRef
73. Multi-Omics Study on the Molecular Mechanism of Anlotinib in Regulating Tumor Metabolism
    Yu Lu et al, 2024, European Journal of Pharmacology CrossRef
74. The mysterious association between adiponectin and endometriosis
    Yong-Qing Zhao et al, 2024, Front. Pharmacol. CrossRef
75. Multi-omics characterization of esophageal squamous cell carcinoma identifies molecular subtypes and therapeutic targets
    Dengyun Zhao et al, 2024 CrossRef
76. Anlotinib induces neuronal‐like differentiation of neuroblastoma by downregulating CRMP5
    Junwen Hu et al, 2024, Molecular Carcinogenesis CrossRef
77. A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: a case report and literature review
    Ying Liu et al, 2024, Pathology - Research and Practice CrossRef
78. Enhancing the management of locally advanced head and neck malignancies and cases with local/neck recurrence and metastasis through the integration of anlotinib with concurrent radiochemotherapy
    Xiaojing Tie et al, 2024 CrossRef
79. Transcriptome and metabolome sequencing identifies glutamate and LPAR1 as potential factors of anlotinib resistance in thyroid cancer
    Bin Liu et al, 2024 CrossRef
80. In vivo study of the effect of anlotinib on the stemness of the lenvatinib-resistant hepatocellular carcinoma cells and the underlying mechanisms
    Jing Zhan et al, 2024, Oncol Transl Med CrossRef
81. Efficacy and safety of gemcitabine/nab-paclitaxel combined with anlotinib and PD-1 inhibitors as a first-line treatment for advanced pancreatic cancer
    Haonan Liu et al, 2024, International Immunopharmacology CrossRef
82. Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents
    Elisabeth Amadeo et al, 2024, Expert Opinion on Investigational Drugs CrossRef
83. Structural Perspectives in the Development of Novel EGFR Inhibitors for the Treatment of NSCLC
    Rahul Makhija et al, 2024, MRMC CrossRef
84. Anlotinib reversed resistance to PD-1 inhibitors in recurrent and metastatic head and neck cancers: a real-world retrospective study
    Jianyun Jiang et al, 2024, Cancer Immunol Immunother CrossRef
85. Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial
    Hua-Qiang Zhou et al, 2024, Sig Transduct Target Ther CrossRef
86. Efficacy and safety of PD‐1 monoclonal antibody combined with interferon‐alpha 1b and anlotinib hydrochloride as the second‐line therapy in patients with unresectable advanced melanoma: A retrospective study
    Bolun Zhao et al, 2024, Cancer Medicine CrossRef
87. Comparative Clinical Efficacy of ‘Concurrent Chemoradiotherapy (CCRT) and Anlotinib’ Than CCRT in Patients with Locally Advanced ESCC
    Gang Wang et al, 2022, Technol Cancer Res Treat CrossRef
88. Combination of anlotinib and sintilimab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma: a single-arm prospective study
    Tianxiao Wang et al, 2024 CrossRef
89. Efficacy, safety, and prognostic factors of anlotinib treatment in advanced non-small cell lung cancer patients
    Aimi Huang et al, 2022 CrossRef
90. Pseudolaric Acid B Inhibits FLT4-induced Proliferation and Migration in Non-small Cell Lung Cancer
    Panpan Lei et al, 2024, ACAMC CrossRef
91. Efficacy and safety of anlotinib combined with S‑1 as a third‑ or later‑line treatment for advanced non‑small cell lung cancer in China: A systematic review and meta‑analysis
    Haonan Xu et al, 2024, Oncol Lett CrossRef
92. The Potential Therapeutic Targets of Anlotinib in Osteosarcoma: Characterization Based on Patient‐Derived Xenografts and Next‐Generation Sequencing
    Zuoyao Long et al, 2024, Cancer Medicine CrossRef
93. Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial
    Jun-Wei Wu et al, 2024, Sig Transduct Target Ther CrossRef
94. Octreotide plus IBI-318 plus anlotinib in the treatment of multiple neuroendocrine metastases of unknown primary lesions: a case report
    Haoyue Qin et al, 2024, Front. Oncol. CrossRef
95. State of Knowledge About Thyroid Cancers in the Era of COVID-19—A Narrative Review
    Agnieszka Bronowicka-Szydełko et al, 2024, Biomedicines CrossRef
96. Angiogenesis and EMT regulators in the tumor microenvironment in lung cancer and immunotherapy
    Taotao Yan et al, 2024, Front. Immunol. CrossRef
97. Anlotinib enhances the pro-apoptotic effect of APG-115 on acute myeloid leukemia cell lines by inhibiting the P13K/AKT signaling pathway
    Rui Zhao et al, 2024, Leukemia Research CrossRef
98. Ammonium Sulfate Gradient-Prepared Anlotinib-Loaded Liposomes for Potent Tumor Therapy with Decreased Side Effect
    Ge Sun et al, 2024, ACS Appl. Nano Mater. CrossRef
99. RTN4IP1 Contributes to ESCC via Regulation of Amino Acid Transporters
    Huifang Wei et al, 2025, Advanced Science CrossRef
100. NGF-TrkA Axis Enhances PDGF-C-Mediated Angiogenesis in Osteosarcoma via miR-29b-3p Suppression: A Potential Therapeutic Strategy Using Larotrectinib
     Sheng-Mou Hou et al, 2025, Life CrossRef